Qiliqiangxin capsule

Developed for: dilated cardiomyopathy · heart failure
Investigated by: China National Center for Cardiovascular Diseases · China Three Gorges University, Yichang, China · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Harbin Medical University · Fudan University
+21 more
· Henan Provincial People's Hospital · Huazhong University of Science and Technology · Jingzhou Central Hospital · Jining Medical University · Ministry of Science and Technology of the People´s Republic of China · RenJi Hospital · Second Affiliated Hospital of Xi'an Jiaotong University · Second Hospital of Shanxi Medical University · Shandong Provincial Hospital · Shanxi Cardiovascular Hospital · The First Affiliated Hospital of Zhengzhou University · The First Affiliated Hospital with Nanjing Medical University · The Second Affiliated Hospital of Harbin Medical University · Tianyou Hospital Affiliated to Wuhan University of Science and Technology · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan No.1 Hospital · Wuhan Pu-Ai Hospital · Wuhan University · Xiangyang Central Hospital · Yunyang Medical College

today NCT01293903 · Ph 4

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT01293903	Jan 2012 → Dec 2015	dilated cardiomyopathy, heart failure	Huazhong University of Science and Technology	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Qiliqiangxin capsule	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01293903 ↗
Modality	Traditional medicine (herbal / TCM)	“a Chinese medicine” NCT01293903 ↗